Cancer BiologybioRxivPreprint
SUMOylation is a Therapeutic Vulnerability in High-risk Neuroblastoma
Antti Kukkula, Saiganesh Sriraman, Verneri Virtanen…·Maria Sundvall
This study identifies SUMOylation as a therapeutic target in high-risk neuroblastoma, showing that SUMO pathway inhibitors like TAK-981 reduce tumor growth and are effective in combination with other therapies.
DOI 10.64898/2026.09.05.749647